देश: इसराइल
भाषा: अंग्रेज़ी
स्रोत: Ministry of Health
ETHINYLESTRADIOL; GESTODENE
BAYER ISRAEL LTD
G03CA01
COATED TABLETS
ETHINYLESTRADIOL 0.03 MG; GESTODENE 0.075 MG
PER OS
Required
BAYER WEIMAR GMBH UND CO.KG, GERMANY
ETHINYLESTRADIOL
Hormonal contraception.
2020-09-30
לע העדוה לע העדוה לע העדוה ( הרמחה ( הרמחה ( הרמחה עדימ עדימ עדימ ל ןולעב )תוחיטב ל ןולעב )תוחיטב ל ןולעב )תוחיטב אפור אפור אפור ןכדועמ( ןכדועמ( ןכדועמ( .102.50 .102.50 .102.50 ) ) ) __ ךיראת 5.10011.03 __ __ םושירה רפסמו תילגנאב רישכת םש 00 - 25622 - 51 - 050 GYNERA םושירה לעב םש _ מ"עב לארשי רייאב _ ה טורפל דעוימ הז ספוט דבלב תורמחה ! תושקובמה תורמחהה ןולעב קרפ נ טסקט יחכו שדח טסקט 4.5 INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTION Interactions Hepatic enzyme inducers Drugs which induce hepatic enzymes (especially cytochrome P450 3A4) increase the metabolism of contraceptive steroids and hence may result in breakthrough bleeding and pregnancy. The following have been shown to have clinically important interactions with COCs: _Antiretroviral agents _ ritonavir; nelfinavir; nevirapine. _ _ _Anticonvulsants _ barbiturates (including phenobarbitone); primidone; phenytoin;- carbamazepine; oxcarbazepine; topiramate. _ _ _Antibiotics/antifungals _ griseofulvin; rifampacin. _ _ _Herbal remedies _ St John’s wort (Hypericum perforatum) Managing interactions with hepatic enzyme inducers Interactions can occur with drugs that induce microsomal enzymes which can result in increased clearance of sex hormones and which may lead to breakthrough bleeding and/or contraceptive failure. Women on short term Interactions Enzyme inducers Interactions can occur with drugs that induce microsomal enzymes (especially cytochrome P450 3A4) which can result in increased clearance of sex hormones and which may lead to breakthrough bleeding and/or contraceptive failure. treatment with any of these drugs should temporarily use a barrier method in addition to the COC or choose another method of contraception. The barrier method shou पूरा दस्तावेज़ पढ़ें
רשואו קדבנ ונכותו תואירבה דרשמ י"ע עבקנ הז ןולע טמרופ THE CONTENT OF THIS LEAFLET WAS APPROVED BY THE MINISTRY OF HEALTH IN JANUARY 2016 AND UPDATED ACCORDING TO THE GUIDELINES OF THE MINISTRY OF HEALTH IN JULY 2019 1. NAME OF THE MEDICINAL PRODUCT Gynera 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Actives: Gestodene 75 micrograms Ethinylestradiol 30 micrograms Excipients: Lactose monohydrate 37.43 mg Sucrose 19.66 mg For full list of excipients, see section 6.1 3. PHARMACEUTICAL FORM Sugar-coated tablets 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Hormonal contraception. The decision to prescribe Gynera should take into consideration the individual woman’s current risk factors, particularly those for venous thromboembolism (VTE), and how the risk of VTE with Gynera compares with other combined hormonal contraceptives (CHCs) (see sections 4.3 and 4.4) 4.2 POSOLOGY AND METHOD OF ADMINISTRATION _First treatment cycle: _1 tablet daily for 21 days, starting on the first day of the menstrual cycle. Contraceptive protection begins immediately. _Subsequent cycles: _Tablet taking from the next pack of Gynera is continued after a 7-day interval, beginning on the same day of the week as the first pack. _Changing from 21-day combined oral contraceptives: _The first tablet of Gynera should be taken on the first day immediately after the end of the previous oral contraceptive course. Additional contraceptive precautions are not required. _ _ _Changing from a combined Every Day pill (28 day tablets): _ Gynera should be started after taking the last active tablet from the Every Day Pill pack. The first Gynera tablet is taken the next day. Additional contraceptive precautions are not then required. _Changing from a progestogen-only pill (POP): _ The first tablet of Gynera should be taken on the first day of bleeding, even if a POP has already been taken on that day. Additional contraceptive precautions are not then required. The remaining progestogen-only पूरा दस्तावेज़ पढ़ें